Cargando…
Optimizing engineered TCR T cell therapy for synovial sarcoma
Autores principales: | D'Angelo, Sandra, Merchant, Melinda, Melchiori, Luca, Zhang, Hua, Pandite, Lini, Holdich, Tom, Binder-Scholl, Gwendolyn, Tap, William, Fortin, Marylene, Peretz, Yoav, Wright, Matthew, Meyers, Paul, Amado, Rafael, Jakobsen, Bent, Mackall, Crystal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645508/ http://dx.doi.org/10.1186/2051-1426-3-S2-P159 |
Ejemplares similares
-
Deep phenotypic characterization of NY-ESO TCR engineered T cells and tumor in patients with advanced myeloma
por: Davila, Eduardo, et al.
Publicado: (2015) -
Preclinical safety testing of an affinity-optimised MAGE-A10 T cell receptor for adoptive T cell therapy
por: Gerry, Andrew, et al.
Publicado: (2015) -
Process improvement and comparability analysis for engineered T cell manufacture
por: Melchiori, Luca, et al.
Publicado: (2014) -
NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma
por: Rapoport, Aaron P., et al.
Publicado: (2015) -
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
por: Ramachandran, Indu, et al.
Publicado: (2019)